adairАллергология и Иммунология в ПедиатрииAllergology and Immunology in Paediatrics2500-11752712-7958Ассоциация детских аллергологов и иммунологов России10.53529/2500-1175-2024-2-38-49adair-145Research ArticleОБЗОРREVIEWПрименение омализумаба и аллерген-специфической иммунотерапии для лечения респираторных аллергических заболеваний у детей и взрослыхUse of omalizumab and allergen-specific immunotherapy for the treatment of respiratory allergic diseases in children and adultshttps://orcid.org/0000-0003-1409-504XПрилуцкийА. С.PrilutskiyA. S.

Прилуцкий Александр Сергеевич — д. м. н., профессор кафедры микробиологии, вирусологии, иммунологии и аллергологии ФГБОУ ВО ДонГМУ имени М. Горького Минздрава России.

83003, Донецк, пр. Ильича, 16

Aleksandr S. Prilutskiy — Doctor of Medical Sciences, Professor of Department of Microbiology, Virology, Immunology and Allergology, Donetsk State Medical University named after M. Gorky.

83003, Donetsk, Ilyich ave., 16

aspr@mail.ruhttps://orcid.org/0000-0002-2175-7841ПрилуцкаяО. А.PrilutskaiaO. A.

Прилуцкая Ольга Александровна — к. м. н., доцент кафедры внутренних болезней № 4 ФГБОУ ВО ДонГМУ имени М. Горького Минздрава России.

83003, Донецк, пр. Ильича, 16

Olga A. Prilutskaia — Cand. Of Medical Sci., Associate Professor of the Department of Therapy No 4, Donetsk State Medical University named after M. Gorky.

83003, Donetsk, Ilyich ave., 16

set1999@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Донецкий государственный медицинский университет имени М. Горького» Министерства здравоохранения Российской ФедерацииFederal State Budgetary Educational Institution of Higher Education “Donetsk State Medical University named after M. Gorky” of the Ministry of Health of the Russian Federation202424062024023849Copyright © Прилуцкий А.С., Прилуцкая О.А., 20242024Прилуцкий А.С., Прилуцкая О.А.Prilutskiy A.S., Prilutskaia O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://adair.elpub.ru/jour/article/view/145

Аллерген-специфическая иммунотерапия является методом лечения и профилактики респираторных аллергических заболеваний. Проведение ее изменяет, улучшает течение аллергических болезней. Одним из перспективных и новых подходов является комбинация аллерген-специфической иммунотерапии с одним из биологических препаратов — омализумабом. В настоящее время таких исследований в мире проведено немного. Из международных баз данных (eLibrary.ru, PubMed, Elsevier, Embase, Cochrane, Web of Science) выбраны 14 работ. Проанализированы и обобщены их результаты. Дана характеристика данных исследований, дизайн их. Описаны полученные результаты безопасности и эффективности сочетанного применения аллерген-специфического лечения и анти-IgE-терапии. Показано, что в большинстве случаев (12 из 14) терапия омализумабом предшествует аллерген-специфической иммунотерапии. Однако длительность комбинированного лечения и схемы применения препаратов, особенности наблюдения за пациентами значительно варьируются. Во всех исследованиях установлены разнообразные положительные эффекты комбинированного применения омализумаба и аллерген-специфической иммунотерапии (улучшение течения болезней, увеличение возможности проведения лечения аллергенами, хорошая переносимость препаратов и др.). Данные исследования очень перспективны. Требуется продолжение их. Необходимо уточнение наиболее рациональных схем применения комбинированного использования анти-IgE-и аллерген-специфической иммунотерапии.

Allergen-specific immunotherapy is a method of treatment and prevention of respiratory allergic diseases. Carrying it out changes and improves the course of allergic diseases. One of the promising and new approaches is the combination of allergen-specific immunotherapy with one of the biological drugs, omalizumab. Currently, few such studies have been carried out in the world. 14 works were selected from international databases (eLibrary.ru, PubMed, Embase, Cochrane, Web of Science). Their results were analyzed and summarized. The characteristics of these studies and their design are given. The results of the safety and effectiveness of the combined use of allergen-specific treatment and anti-IgE therapy are described. It was shown that in most cases (13 out of 14), omalizumab therapy precedes allergen-specific immunotherapy. However, the duration of combination treatment, drug regimens, and patient monitoring vary significantly. All studies have established a variety of positive effects of the combined use of omalizumab and allergen-specific immunotherapy (improvement of the course of diseases, increased possibility of treatment with allergens, good tolerability of drugs, etc.). These studies are very promising. Their continuation is required. It is necessary to clarify the most rational schemes for the combined use of anti-IgE and allergen-specific immunotherapy.

аллерген-специфическая иммунотерапиядетивзрослыеомализумаббиологические препаратыанти-IgE-терапияринитастмааллергенылечениеallergen-specific immunotherapychildrenadultsomalizumabbiological drugsanti-IgE therapyrhinitisasthmaallergenstreatmentReferencesKarol MH. Respiratory allergy: what are the uncertainties? Toxicology. 2002; 181–182: 305–310. https://doi.org/10.1016/s0300-483x(02)00298-6.x.Karol MH. Respiratory allergy: what are the uncertainties? Toxicology. 2002; 181–182: 305–310. https://doi.org/10.1016/s0300-483x(02)00298-6.x.Schiavoni G, D’Amato G, Afferni C. The dangerous liaison between pollens and pollution in respiratory allergy. Ann Allergy Asthma Immunol. 2017; 118 (3): 269–275. https://doi.org/10.1016/j.anai.2016.12.019.Schiavoni G, D’Amato G, Afferni C. The dangerous liaison between pollens and pollution in respiratory allergy. Ann Allergy Asthma Immunol. 2017; 118 (3): 269–275. https://doi.org/10.1016/j.anai.2016.12.019.Linneberg A. The increase in allergy and extended challenges. Allergy. 2011; Suppl 95: 1–3. https://doi.org/10.1111/j.1398-9995.2011.02619.x.Linneberg A. The increase in allergy and extended challenges. Allergy. 2011; Suppl 95: 1–3. https://doi.org/10.1111/j.1398-9995.2011.02619.x.Di Lorenzo G, Melluso M, Rodolico A, Seidita A. Allergic Diseases in the Elderly. Transl Med UniSa. 2023; 25 (2): 52–62. https://doi.org/10.37825/2239-9747.1046.Di Lorenzo G, Melluso M, Rodolico A, Seidita A. Allergic Diseases in the Elderly. Transl Med UniSa. 2023; 25 (2): 52–62. https://doi.org/10.37825/2239-9747.1046.Moitra S, Mahesh PA, Moitra S. Allergic rhinitis in India. S. Clin Exp Allergy. 2023; 53 (7): 765–776. https://doi.org/10.1111/cea.14295.Moitra S, Mahesh PA, Moitra S. Allergic rhinitis in India. S. Clin Exp Allergy. 2023; 53 (7): 765–776. https://doi.org/10.1111/cea.14295.Ильина НИ, Курбачева ОМ, Павлова КС. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением анти-IgE антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008; 2: 17–27.Il’ina NI, Kurbacheva OM, Pavlova KS. Vozmozhnosti kombinirovannogo primeneniya allergen-spetsificheskoy immunoterapii s parallel’nym vvedeniyem anti-IgE antitel v lechenii patsiyentov s atopicheskimi zabolevaniyami. Rossiyskiy allergologicheskiy zhurnal. 2008; 2: 17–27. (In Russ.)Семенова ИВ, Новиков ДК, Ищенко ОВ. Медиаторная терапия пыльцевой гиперчувствительности. Достижения фундаментальной клинической медицины и фармации: Материалы 73-й научной сессии ВГМУ. 29–30 января 2018 г., Витебск, Белоруссия. Витебский государственный медицинский университет. 2018: 226–228.Semenova IV, Novikov DK, Ishchenko OV. Mediatornaya terapiya pyl’tsevoy giperchuvstvitel’nosti. Dostizheniya fundamental’noy klinicheskoy meditsiny i farmatsii: Materialy 73-y nauchnoy sessii VGMU. 29–30 yanvarya 2018 g., Vitebsk, Belorussiya. Vitebskiy gosudarstvennyy meditsinskiy universitet. 2018: 226–228. (In Russ.)Татаурщикова НС, Максимова АВ. Аллерген-специфическая иммунотерапия: поиск эффективных решений. Эффективная фармакотерапия. 2023; 19 (26): 34–42. https://doi.org/10.33978/2307-3586-2023-19-26-34-42.Tataurshchikova NS, Maksimova AV. Allergen-spetsificheskaya immunoterapiya: poisk effektivnykh resheniy. Effektivnaya farmakoterapiya. 2023; 19 (26): 34–42. https://doi.org/10.33978/2307-3586-2023-19-26-34-42. (In Russ.)Tiligada E, Gafarov D, Zaimi M, Vitte J, Levi-Schaffer F. Novel Immunopharmacological Drugs for treatment of Allergic Diseases. Annu Rev Pharmacol Toxicol. 2024; 64: 481–506. https://doi.org/10.1146/annurev-pharmtox-051623-091038.Tiligada E, Gafarov D, Zaimi M, Vitte J, Levi-Schaffer F. Novel Immunopharmacological Drugs for treatment of Allergic Diseases. Annu Rev Pharmacol Toxicol. 2024; 64: 481–506. https://doi.org/10.1146/annurev-pharmtox-051623-091038.Arshad H, Lack G, Durham SR, Penagos M, Larenas-Linnemann D, Halken SJ. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease. Allergy Clin Immunol Pract. 2024; 12 (1): 45–56. https://doi.org/10.1016/j.jaip.2023.10.013.Arshad H, Lack G, Durham SR, Penagos M, Larenas-Linnemann D, Halken SJ. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease. Allergy Clin Immunol Pract. 2024; 12 (1): 45–56. https://doi.org/10.1016/j.jaip.2023.10.013.Смолкин ЮС, Трусова ОВ, Алискандиева ЗА, Барычева ЛЮ, Богомазов АД, Бочарова КА, Емелина ЮН, Камаев АВ, Ларькова ИА, Мархайчук АЗ, Масальский СС, Мигачева НБ, Прилуцкий АС, Стежкина ЕВ, Файзуллина РМ, Хакимова РФ, Чурюкина ЭВ, Шахова НВ, Шилова ТВ. Аллерген-специфическая иммунотерапия у детей. Согласительный документ Ассоциации детских аллергологов и иммунологов России (позиционная статья). Аллергология и иммунология в педиатрии. 2023; 4: 5–30. https://doi.org/10.53529/2500-1175-2023-4-5-30.Smolkin YUS, Trusova OV, Aliskandiyeva ZA, Barycheva LYU, Bogomazov AD, Bocharova KA, Yemelina YUN, Kamayev AV, Lar’kova IA, Markhaychuk AZ, Masal’skiy SS, Migacheva NB, Prilutskiy AS, Stezhkina YEV, Fayzullina RM, Khakimova RF, Churyukina EV, Shakhova NV, Shilova TV. Allergen-specific immunotherapy in children.Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper). Allergology and Immunology in Pediatrics. 2023; 3: 5–30. https://doi.org/10.53529/2500-1175-2023-4-5-30. (In Russ.)Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int. 2020; 69 (4): 549–560. https://doi.org/10.1016/j.alit.2020.08.002.Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int. 2020; 69 (4): 549–560. https://doi.org/10.1016/j.alit.2020.08.002.Matsuda M, Terada T, Kitatani K, Kawata R, Nabe T. Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy. Front Allergy. 2022; 3: 981126. https://doi.org/10.3389/falgy.2022.981126.Matsuda M, Terada T, Kitatani K, Kawata R, Nabe T. Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy. Front Allergy. 2022; 3: 981126. https://doi.org/10.3389/falgy.2022.981126.Bernstein DI, Wanner M, Borish L, LissGM. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004; 113 (6): 1129–1136. https://doi.org/10.1016/j.jaci.2004.02.006.Bernstein DI, Wanner M, Borish L, LissGM. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004; 113 (6): 1129–1136. https://doi.org/10.1016/j.jaci.2004.02.006.Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008–2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. Allergy Asthma Proc. 2020; 41 (2): 108–111. https://doi.org/10.2500/aap.2020.41.200001.Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008–2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. Allergy Asthma Proc. 2020; 41 (2): 108–111. https://doi.org/10.2500/aap.2020.41.200001.Winslow AW, Turbyville JC, Sublett JW, Sublett JL, Pollard SJ. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2016; 117 (5): 542–545. https://doi.org/10.1016/j.anai.2016.09.005.Winslow AW, Turbyville JC, Sublett JW, Sublett JL, Pollard SJ. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy. Ann Allergy Asthma Immunol. 2016; 117 (5): 542–545. https://doi.org/10.1016/j.anai.2016.09.005.Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Med Gen Med. 2005; 7 (1): 27.Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Med Gen Med. 2005; 7 (1): 27.Sutton BJ, Davies AM. Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev. 2015; 268 (1): 222–235. https://doi.org/10.1111/imr.12340.Sutton BJ, Davies AM. Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev. 2015; 268 (1): 222–235. https://doi.org/10.1111/imr.12340.19. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017; 72 (4): 519–533. https://doi.org/10.1111/all.13083.19. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017; 72 (4): 519–533. https://doi.org/10.1111/all.13083.Maggi L, Rossettini B, Montaini G, Matucci A, Vultaggio A, Mazzoni A, Palterer B, Parronchi P, Maggi E, Liotta F, Annunziato F, Cosmi L. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018; 48 (12): 2005–2014. https://doi.org/10.1002/eji.201847668.Maggi L, Rossettini B, Montaini G, Matucci A, Vultaggio A, Mazzoni A, Palterer B, Parronchi P, Maggi E, Liotta F, Annunziato F, Cosmi L. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018; 48 (12): 2005–2014. https://doi.org/10.1002/eji.201847668.Poddighe D, Vangelista L. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticarial. Cell Immunol. 2020; 358: 104215. https://doi.org/10.1016/j.cellimm.2020.104215.Poddighe D, Vangelista L. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticarial. Cell Immunol. 2020; 358: 104215. https://doi.org/10.1016/j.cellimm.2020.104215.Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O’Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines — recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75 (5): 1043–1057. https://doi.org/10.1111/all.14235.Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O’Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines — recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75 (5): 1043–1057. https://doi.org/10.1111/all.14235.Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2022; 10 (2): 422–432. https://doi:10.1016/j.jaip.2021.10.059.Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2022; 10 (2): 422–432. https://doi:10.1016/j.jaip.2021.10.059.Bayar Muluk N, Cingi C.Biologics in allergic rhinitis. Eur Rev Med Pharmacol Sci. 2023; 27 (5 Suppl): 43–52. https://doi.org/10.26355/eurrev_202310.Bayar Muluk N, Cingi C.Biologics in allergic rhinitis. Eur Rev Med Pharmacol Sci. 2023; 27 (5 Suppl): 43–52. https://doi.org/10.26355/eurrev_202310.Yu L, Zhang H, Pan J, Ye L. Pediatric usage of Omalizumab: A promising one. World Allergy Organ J. 2021; 14 (12): 100614. https://doi:10.1016/j.waojou.2021.100614.Yu L, Zhang H, Pan J, Ye L. Pediatric usage of Omalizumab: A promising one. World Allergy Organ J. 2021; 14 (12): 100614. https://doi:10.1016/j.waojou.2021.100614.Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109 (2): 274–280. https://doi.org/10.1067/mai.2002.121949.Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109 (2): 274–280. https://doi.org/10.1067/mai.2002.121949.Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, Kuehr J, Zielen S, Schauer U, Kamin W, Von Berg A, Hammermann J, Weinkauf B, Weidinger G, Stenglein S, Wahn U. Omalizumab Rhinitis Study Group. Allergy. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59 (9): 973–979. https://doi.org/10.1111/j.1398-9995.2004.00552.x.Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, Kuehr J, Zielen S, Schauer U, Kamin W, Von Berg A, Hammermann J, Weinkauf B, Weidinger G, Stenglein S, Wahn U. Omalizumab Rhinitis Study Group. Allergy. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59 (9): 973–979. https://doi.org/10.1111/j.1398-9995.2004.00552.x.Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010; 21 (1 Pt 2): e160–5.Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010; 21 (1 Pt 2): e160–5.Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Immune Tolerance Network Group Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117 (1): 134–140. https://doi.org/10.1016/j.jaci.2005.09.036.Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Immune Tolerance Network Group Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117 (1): 134–140. https://doi.org/10.1016/j.jaci.2005.09.036.Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39 (2): 271–279. https://doi.org/10.1111/j.1365-2222.2008.03121.x.Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39 (2): 271–279. https://doi.org/10.1111/j.1365-2222.2008.03121.x.Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, Klein C, Wahn U. DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013; 24 (5): 427–433. https://doi.org/10.1111/pai.12098.Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, Klein C, Wahn U. DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013; 24 (5): 427–433. https://doi.org/10.1111/pai.12098.Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010; 125: 383–389. https://doi.org/10.1016/j.jaci.2009.11.022.Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010; 125: 383–389. https://doi.org/10.1016/j.jaci.2009.11.022.Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski L, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland. Arch Med Sci. 2015; 11 (4): 901–904. https://doi.org/10.5114/aoms.2015.48546.Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski L, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland. Arch Med Sci. 2015; 11 (4): 901–904. https://doi.org/10.5114/aoms.2015.48546.Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2015; 25: 829–832. https://doi.org/10.1111/pai.12306.Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2015; 25: 829–832. https://doi.org/10.1111/pai.12306.Наконечная АД, Галимова АА. Опыт проведения аллерген-специфической иммунотерапии на фоне анти-IgE терапии у ребенка с поллинозом. Российский педиатрический журнал. 2021; 24 (S): 41.Nakonechnaya AD, Galimova AA. Opyt provedeniya allergen-spetsificheskoy immunoterapii na fone anti-IgE terapii u rebenka s pollinozom. Rossiyskiy pediatricheskiy zhurnal. 2021; 24 (S): 41. (In Russ.)Valdesoiro-Navarrete L, León ME, Rodríguez M, Indiveri M, Ayats R, Larramona H, González MG, de la Cruz ÒA, García MB. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma. Allergol Immunopathol (Madr). 2022; 50 (2): 1–6. https://doi.org/10.15586/aei.v50i2.469.Valdesoiro-Navarrete L, León ME, Rodríguez M, Indiveri M, Ayats R, Larramona H, González MG, de la Cruz ÒA, García MB. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma. Allergol Immunopathol (Madr). 2022; 50 (2): 1–6. https://doi.org/10.15586/aei.v50i2.469.Bozek A, Kozłowska R, Misiołek M, Ścierski W, Gawlik R. Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis. Hum Vaccin Immunother. 2022; 18 (6): 2097818. https://https://doi:10.1080/21645515.2022.2097818.Bozek A, Kozłowska R, Misiołek M, Ścierski W, Gawlik R. Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis. Hum Vaccin Immunother. 2022; 18 (6): 2097818. https://https://doi:10.1080/21645515.2022.2097818.Bożek A, Fischer A, Bogacz-Piaseczynska A, Canonica GW. Adding a biologic to allergen immunotherapy increases treatment efficacy. ERJ Open Res. 2023; 9 (2): 00639–2022. https://doi.org/10.1183/23120541.00639-2022.Bożek A, Fischer A, Bogacz-Piaseczynska A, Canonica GW. Adding a biologic to allergen immunotherapy increases treatment efficacy. ERJ Open Res. 2023; 9 (2): 00639–2022. https://doi.org/10.1183/23120541.00639-2022.Bozek A, Rogala B, Miodonska M, Canonica GW. Progressive clinical effects of the combination omalizumab and HDM — allergen immunotherapy in asthma. J Asthma. 2024; 61 (6): 532–538. https://doi.org/10.1080/02770903.2023.2293057.Bozek A, Rogala B, Miodonska M, Canonica GW. Progressive clinical effects of the combination omalizumab and HDM — allergen immunotherapy in asthma. J Asthma. 2024; 61 (6): 532–538. https://doi.org/10.1080/02770903.2023.2293057.Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, Kamin W, Berg AV, Wahu U, Zielen S. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004; 34 (7): 1079–1085. https://doi.org/10.1111/j.1365-2222.2004.01998.x.Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, Kamin W, Berg AV, Wahu U, Zielen S. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004; 34 (7): 1079–1085. https://doi.org/10.1111/j.1365-2222.2004.01998.x.Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Immune Tolerance Network Group. J Allergy Clin Immunol. 2007; 120 (3): 688–695. https://doi.org/10.1016/j.jaci.2007.05.034.Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Immune Tolerance Network Group. J Allergy Clin Immunol. 2007; 120 (3): 688–695. https://doi.org/10.1016/j.jaci.2007.05.034.

The authors declare that there are no conflicts of interest present.